The global PD-1 and PD-L1 inhibitors market was valued at US$ 28,497.82 Mn in 2020 and is projected to grow at a CAGR of 18.8% during the forecast period (2021 – 2029). The global PD-1 and PD-L1 inhibitors market is being driven by rising demand for ideal cancer therapeutics, as well as favourable reimbursement policies offered by vendors and insurance providers in some countries. Furthermore, the other prominent factors driving the market growth is the sharp increase in the global prevalence of various cancers, as well as growing elderly population across the world. According to the World Health Organization, cancer is the leading cause of death worldwide, and accounted for nearly 9.6 million deaths in 2018, with lung cancer being the most common cause of death, taking account for 1.76 million deaths. Increased volume of patient pool has resulted in increased demand for adequate therapies. Simultaneously, increased initiatives by key companies towards research and development of PD-1 and PD-L1 inhibitors are expected to drive the growth of global PD-1 and PD-L1 inhibitors market over the forecast period. For instance, in January 2021, BeiGene, Ltd., a commercial-stage biotechnology company involved in developing and commercializing innovative medicines globally, announced a collaboration and license agreement with Novartis Pharma AG to develop, manufacture, and commercialize BeiGene's anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, Iceland, Liechtenstein, Russia, European Union member countries, the United Kingdom, Norway, Switzerland, and Japan. The companies have agreed to collaborate on the development of Tislelizumab in these licensed countries, with Novartis responsible for regulatory submissions after a transition period and commercialization following the regulatory approval. Furthermore, both companies may conduct clinical trials around the world to investigate tislelizumab combinations with other cancer treatments.
How Absolute Market Insights is unique in nature?
The research report on PD-1 and PD-L1 Inhibitors Market will include extensive information based on the following pointers:
- Global Market size and forecast values (2015 – 2029), in terms of revenue (US$ Million) by segments/sub-segments; wherein 2015 to 2019 has been considered as historic years, 2020 as the base year, while 2021 to 2029 has been considered as the forecast period.
- Split of the market revenue (US$ Million) into all the relevant segments & sub-segments across all major regions/countries.
- Market Determinants and Influencing Factors
- Macro-Economic and Micro-Economic Indicators
- Market Dynamics
- Trends on Global PD-1 and PD-L1 Inhibitors Market
- Exclusive Details on the Effect of the Pandemic
- Porter’s Five Forces Analysis
- Regulatory Landscape
- Overview on Clinical Development of PD-1/PD-L1 Agents
- Competitor Landscape
- Product Benchmarking
- Market Share Analysis, 2020
- Global Presence and Growth Strategies
- The final report will include competitive product benchmarking which will encompass comparison of varied services offered by different market participants on the basis of their features and capabilities that will help you to understand their market offerings. Furthermore, for each company, we will provide information regarding company details, company overview, product offerings, key developments, financial analysis, and SWOT analysis and business strategies.
- The research study specific to a region, including North America, Europe, Asia Pacific, Middle East & Africa and Latin America, is also available.
- We offer our reports in different languages which include German, Chinese, French, Russian, Spanish, Arabic, Japanese and Korean amongst others.
PD-L1 Segment is gaining traction in the PD-1 and PD-L1 Inhibitors Market
Immune suppression is linked to cancer growth and progression. Cancer cells have the ability to activate immune checkpoint pathways with immunosuppressive functions. Among the immune checkpoint inhibitors, PD-1 and PD-L1 inhibitors demonstrated promising therapeutic outcomes; some have been approved for specific cancer treatments, while others are still in clinical trials. Atezolizumab (Tecentriq), Avelumab (Bavencio), and other drugs are included in the PD-L1 inhibitor.
In 2019, AstraZeneca presented three-year overall survival (OS) results from the Phase III PACIFIC trial of Imfinzi (durvalumab) in unresectable, Stage III non-small cell lung cancer (NSCLC) in Chicago. Imfinzi is a human monoclonal antibody that binds to PD-L1 and inhibits its interaction with PD-1 and CD80, thus counteracting the tumour’s immune-evasion tactics and releasing immune response inhibition. These findings show a durable and sustained OS benefit in patients with unresectable cancer; at three years, the OS rate for patients receiving Imfinzi was 57 percent while for placebo following concurrent CRT was 43.5 percent.
Request Sample Copy of This Report:https://www.absolutemarketsinsights.com/request_sample.php?id=1051
Non-small Cell Lung Cancer (NSCLC) is expected to Witness Fastest Growth over the Forecast Period
An increasing number of non-small cell lung cancer diagnoses, as well as increased awareness in developed and developing economies, are contributing to the non-small cell lung cancer segment’s growth in the PD-1 and PD-L1 inhibitors market. NSCLC accounts for roughly 85 percent of all lung cancers. NSCLC necessitates a comprehensive staging workup to determine the degree of disease, as stage plays a significant role in treatment selection. In April 2018, Bristol-Myers Squibb Company released the findings of the pivotal, randomized Phase 3 CheckMate -078 study comparing Opdivo (nivolumab) versus docetaxel in a largely Chinese population with previously treated advanced non-small cell lung cancer (NSCLC). There was an improvement in overall survival regardless of PD-L1 expression or tumour histology.
The Impact of COVID-19 Pandemic on the Global PD-1 and PD-L1 Inhibitors Market
COVID-19 is an infectious disease caused by a virus that afflicted people all over the world in 2020. It primarily affects the lungs, causing symptoms such as fever, dry cough, fatigue, and so on. Cancer patients are more vulnerable as a result of the tumour and the anticancer treatment. At the same time, because of the need for regular treatment and testing in hospitals, they are at a higher risk of COVID-19 exposure. However, in the middle stage of the pandemic, healthcare providers are shifting their preferences to other diseases. Similar initiatives by companies to adapt more seamlessly to changing market conditions point towards positive growth prospects for the global PD-1 and PD-L1 inhibitors market over the forecast period.
North America region held the Highest Share in the PD-1 and PD-L1 inhibitors Market
According to the global figures, North America region accounted for the highest share in the global PD-1 and PD-L1 inhibitors market. The dominance is due to the rising prevalence of chronic diseases such as diabetes, skin cancer, urothelial carcinomas, and lung cancers, as well as the presence of a large population of baby boomers in the United States, which necessitated effective treatment. According to American Cancer Society Inc., in 2020, lung cancer was the second most common type cancer, accounting for 135,720 deaths in both men and women. According to the statistics, approximately 13% of all lung cancers in the United States are small cell lung cancer (SCLC) and 84 percent are non-small cell lung cancer (NSCLC), which is expected to continue in the future, resulting in increased demand in the PD-1 and PD-L1 inhibitors market
The key market participants operating in the global PD-1 and PD-L1 Inhibitors Market are:
- Amgen Inc.
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Other Market Participants
Enquiry Before Buying:https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=1051
Global PD-1 and PD-L1 Inhibitors Market:
- By Type
- PD-1 (Pembrolizumab, Nivolumab, Etc.)
- PD-L1 (Atezolizumab, Avelumab, Etc.)
- By Application
- Non-small Cell Lung Cancer (NSCLC)
- Urothelial Carcinoma (UC)
- Esophageal Cancer
- Head and Neck Cancer
- By Region
- North America
- Rest of North America
- The UK
- Nordic Countries
- Benelux Union
- The Netherlands
- Rest of Europe
- Asia Pacific
- New Zealand
- South Korea
- Southeast Asia
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
- Latin America
- Rest of Latin America
- North America
Purchase the Report:https://www.absolutemarketsinsights.com/checkout?id=1051
Company: Absolute Markets Insights
Email Id: [email protected]
Phone: IN +917400242424, US +1-510-420-1213
Contact Name: Shreyas Tanna